Clinical trial nabs SEC attention

Share this article:

A Securities and Exchange Commission investigation has added a new angle to the clinical trial world: the potential for insider trading. The government agency announced Monday that it has accused two California doctors of illegally using non-public information to make money.

The SEC says the two doctors had agreed to provide services as part of a clinical trial for GTx, which was testing its prostate cancer drug Capesaris. The doctors were paid for their participation in the study, and the SEC notes the contracts “contained strict confidentiality provisions” that kept the physicians from “using non-public information about the trials for any purpose other than rendering services.”

The SEC alleges that the doctors sold GTx stock after the drugmaker said the FDA idled the trials over safety concerns, and before GTx made this news public. The SEC says the doctors saved close to a combined $46,000 because they were able to unload stock before the news depressed share prices.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.